The August Krogh Section for Human Physiology, Department of Nutrition, Exercise and Sports (Experimental Site), University of Copenhagen, Copenhagen, Denmark.
Vascular Biology Group, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Br J Clin Pharmacol. 2023 Jul;89(7):2179-2189. doi: 10.1111/bcp.15688. Epub 2023 Feb 24.
The aim of this study is to examine whether colchicine improves β adrenoceptor-mediated vasodilation in humans by conducting a double-blinded, placebo-controlled intervention study. Colchicine treatment has known beneficial effects on cardiovascular health and reduces the incidence of cardiovascular disease. Studies in isolated rodent arteries have shown that colchicine can enhance β adrenoceptor-mediated vasodilation, but this has not been determined in humans.
Middle-aged men with essential hypertension were randomly assigned firstly to acute treatment with either 0.5 mg colchicine (n = 19) or placebo (n = 12). They were subsequently re-randomized for 3 weeks of treatment with either colchicine 0.5 mg twice daily (n = 16) or placebo (n = 15) followed by a washout period of 48-72 h. The vasodilator responses to isoprenaline, acetylcholine and sodium nitroprusside were determined as well as arterial pressure, arterial compliance and plasma inflammatory markers.
Acute colchicine treatment increased isoprenaline (by 38% for the highest dose) as well as sodium nitroprusside (by 29% main effect) -induced vasodilation but had no effect on the response to acetylcholine. The 3-week colchicine treatment followed by a washout period did not induce an accumulated or sustained effect on the β adrenoceptor response, and there was no effect on arterial pressure, arterial compliance or the level of measured inflammatory markers.
Colchicine acutely enhances β adrenoceptor- and nitric oxide-mediated changes in vascular conductance in humans, supporting that the mechanism previously demonstrated in rodents, translates to humans. The results provide novel translational evidence for a transient enhancing effect of colchicine on β adrenoceptor-mediated vasodilation in humans with essential hypertension.
Preclinical studies in isolated rodent arteries have shown that colchicine can enhance β adrenoceptor-mediated vasodilation. Here we show that this effect of colchicine can be translated to humans. Acute colchicine treatment was found to increase both isoprenaline- and sodium nitroprusside-induced vasodilation. The study provides the first translational evidence for a transient β adrenoceptor-mediated vasodilatory effect of colchicine in humans. The finding of an acute effect suggests that it may be clinically important to maintain an adequate bioavailability of colchicine.
本研究旨在通过双盲、安慰剂对照干预研究,检验秋水仙碱是否能改善人类β肾上腺素能介导的血管舒张。秋水仙碱治疗对心血管健康有已知的有益作用,并降低心血管疾病的发病率。在分离的啮齿动物动脉中的研究表明,秋水仙碱可以增强β肾上腺素能介导的血管舒张,但尚未在人类中确定。
中年原发性高血压男性随机分为急性治疗组,分别给予 0.5mg 秋水仙碱(n=19)或安慰剂(n=12)。随后,他们被重新随机分为 3 周的秋水仙碱 0.5mg 每日两次治疗组(n=16)或安慰剂治疗组(n=15),随后进行 48-72 小时的洗脱期。测定异丙肾上腺素、乙酰胆碱和硝普钠的血管舒张反应,以及动脉压、动脉顺应性和血浆炎症标志物。
秋水仙碱急性治疗增加了异丙肾上腺素(最高剂量增加 38%)和硝普钠(增加 29%的主效应)诱导的血管舒张,但对乙酰胆碱的反应没有影响。3 周的秋水仙碱治疗后进行洗脱期,不会对β肾上腺素受体反应产生累积或持续的影响,也不会对动脉压、动脉顺应性或测量的炎症标志物水平产生影响。
秋水仙碱在人类中急性增强β肾上腺素能和一氧化氮介导的血管传导变化,支持在啮齿动物中证明的机制在人类中也有转化。结果为秋水仙碱在原发性高血压患者中对β肾上腺素能介导的血管舒张的短暂增强作用提供了新的转化证据。